Carol Gallagher
Partner @ New Enterprise Associates
San Diego, United States
Carol Gallagher is a Series B investor at New Enterprise Associates in San Diego focused on Biotechnology and Health Care. Carol Gallagher joined NEA in October, 2014. She is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with more than 25 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and sheserved as an independent director on multiple Boards including Aragon Pharmaceuticals, which was acquired in 2013 by Johnson and Johnson for $650 million upfront and a total consideration of $1 billion. From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. During her tenure as CEO at Calistoga Pharmaceuticals, Dr. Gallagher raised $80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for $375 million and a total consideration of $600 million. Gilead has continued to rapidly advance registration trials of ZYDELIG in patients with certain types of leukemia and lymphoma. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Carol Gallagher invests in
Stages Carol Gallagher invests in
Countries Carol Gallagher invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (67%)
- Health Care 3 (33%)
- Medical 2 (22%)
- Therapeutics 2 (22%)
- Pharmaceutical 2 (22%)
Stage
- Series B 4 (44%)
- Series C 2 (22%)
- Seed 1 (11%)
- Series A 1 (11%)
- Venture - Series Unknown 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Recludix pharma is a developing platform to discover potent and selective inhibitors of challenging protein targets. The platform approach integrates custom generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. | $60M / Series A / Nov 15, 2021 | ||
| ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’sgold-standard biochemical assays at a very low cost.ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California. | $28M / Series C / Dec 17, 2019 | ||
| Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. | $30M / Venture - Series Unknown / Aug 09, 2018 | ||
| Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of noveldrug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. | $65M / Series C / Jun 06, 2018 | ||
| Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, isdesigned to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity. | $62M / Series B / Dec 13, 2017 | ||
| Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of noveldrug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. | $22M / Series B / Dec 07, 2017 | ||
| Good2Go automated access and virtual queuing technology give customers secure, frictionless access to the products and services they want while deterring crime and misuse. Businesses gain immediate ROI. Only Good2Go offers a single access tool for an infinite number of entry points. Our simple QR code process is highly scalable across industries.From simple restroom and dressing room solutions to a single point of access for every conceivable customer touch-point — transportation, entertainment, order fulfillment, EV interface, travel, transport, and more — it’s limitless. Elevate your brand with Good2Go. | $7M / Seed / Sep 21, 2017 | ||
| Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer. | $37M / Series B / Aug 17, 2016 | ||
| Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. | $62M / Series B / Jan 05, 2016 |
Co-Investors
New Enterprise Associates is a venture capital firm that invests in technology and healthcare startups. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. The company focuses on the technology and healthcare industries.
New Enterprise Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Sharata
Associate
|
|||
Anthony Florence
General Partner
|
|||
Bala Deshpande
Sr. Managing Director, India
|
|||
Hilarie Koplow-McAdams
Venture Partner
|
|||
Jay Graf
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Carol Gallagher invest in?
Carol Gallagher invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Carol Gallagher?
Public channels for Carol Gallagher include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Carol Gallagher last invest?
The most recent investment recorded for Carol Gallagher closed in Nov 2021. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
